Yingye Zheng is a biostatistician who develops novel statistical tools for medical decision-making related to disease screening, diagnosis, prognosis and outcome prediction. Her work includes evaluating how useful potential biomarkers and disease-risk models will be/are for real patients in the clinic and how to use electronic medical records to evaluate cancer screening techniques.
She also studies how to use molecular signals that change over time (called longitudinal biomarkers) to dynamically predict risk and monitor patients’ disease status. Zheng is an investigator in the Fred Hutch-based Data Management and Coordinating Center of the Early Detection Research Network, or EDRN, a national network that develops, evaluates and validates biomarkers for early detection and risk assessment for cancer. She also is co-principal investigator of the Hutch-based Coordinating Center for the Population-based Research to Optimize the Screening Process II, or PROSPR II, a national consortium that aims to reduce false-positive and false-negative test results in cancer screening.
Yingye Zheng is a biostatistician who develops novel statistical tools for medical decision-making related to disease screening, diagnosis, prognosis and outcome prediction. Her work includes evaluating how useful potential biomarkers and disease-risk models will be/are for real patients in the clinic and how to use electronic medical records to evaluate cancer screening techniques.
She also studies how to use molecular signals that change over time (called longitudinal biomarkers) to dynamically predict risk and monitor patients’ disease status. Zheng is an investigator in the Fred Hutch-based Data Management and Coordinating Center of the Early Detection Research Network, or EDRN, a national network that develops, evaluates and validates biomarkers for early detection and risk assessment for cancer. She also is co-principal investigator of the Hutch-based Coordinating Center for the Population-based Research to Optimize the Screening Process II, or PROSPR II, a national consortium that aims to reduce false-positive and false-negative test results in cancer screening.